What is New In Our Community
Get access to our breaking news, company information, publications, and resources
Press Releases
Illumina and Pillar Biosciences Partner to Improve Access to Personalized Cancer Treatment Options
July 25, 2023
No Comments
SAN DIEGO, JULY 25, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Pillar Biosciences Inc., the
Pillar Biosciences and KeyGene Enter into Licensing Agreement
April 13, 2023
No Comments
NATICK, Mass. and WAGENINGEN, Netherlands, April 13, 2023 /PRNewswire/ — Pillar Biosciences, Inc., the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) tests to localize testing and
Pillar Biosciences Receives College of American Pathologists (CAP) Accreditation
February 7, 2023
No Comments
NATICK, Mass.–(BUSINESS WIRE)–Pillar Biosciences, Inc., the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) tests to localize testing and reduce time to
Resources
2024
2023
2022
2021
2020
2019
Earlier Presentations
2024
2023
2022
2021
2020
2019
Earlier Presentations
2024
2023
2022
2021
2020
2019
2018
Earlier Posters
2024
2023
2022
2021
2020
2019
2018
Earlier Posters
2024
2023
2022
2021
2019
2018
Earlier Publications
2024
2023
May 05, 2023
Minimizing Sample Failure Rates for Challenging Clinical Tumor Samples
Learn more2022
August 08, 2022
Quality metrics for enhanced performance of an NGS panel using single-vial amplification technology
Learn moreNovember 03, 2022
Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing?
Learn more
February 01, 2022
Abnormal TP53 Predicts Risk of Progression in Patients With Barrett’s Esophagus Regardless of a Diagnosis of Dysplasia
Learn more
June 17, 2022
Localizing next-generation sequencing testing for cancer patients
Learn more2021
Sept 30, 2021
Effective and Accurate CNV Calling Using the PiVAt Bioinformatics Platform
Learn More
2019
Jan 05, 2019
Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients
Learn More
2018
Aug 28, 2018
Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing
Learn More
Earlier Publications
Jul 12, 2017
Amplification of overlapping DNA amplicons in a single-tube multiplex PCR for targeted next-generation sequencing of BRCA1 and BRCA2
Learn More
Apr 06, 2017
Feasibility Study of Molecular Profiling of Gastric Cancer Specimens From Rwanda
Learn More
Pillar Biosciences Inc., 9 Strathmore Rd., Natick MA, 01760